Catenin Beta 1 (Beta Catenin or CTNNB1) – Pipeline Review, H2 2017

“The Report Catenin Beta 1 (Beta Catenin or CTNNB1) – Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 (Beta Catenin or CTNNB1) – Pipeline Review, H2 2017, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Catenin Beta 1 (Beta Catenin or CTNNB1) – Catenin beta-1 or -catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Gastrointestinal, Genetic Disorders and Other Diseases which include indications Colorectal Cancer, Familial Adenomatous Polyposis, Hepatic (Liver) Tumor, Liver Fibrosis, Melanoma, Orphan Diseases, Ovarian Cancer, Pancreatic Cancer, Scar and Solid Tumor.

Get Sample Copy Of This Report @

https://www.marketresearchreports.biz/sample/sample/1343241

Furthermore, this report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

– The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)

– The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

View Report @ https://www.marketresearchreports.biz/reports/1343241/catenin-beta-1-beta-catenin-or-ctnnb1-pipeline-review-h2-2017-market-research-reports

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Send An Enquiry Request @

https://www.marketresearchreports.biz/sample/enquiry/1343241

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Catenin Beta 1 (Beta Catenin or CTNNB1) – Overview 7

Catenin Beta 1 (Beta Catenin or CTNNB1) – Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Catenin Beta 1 (Beta Catenin or CTNNB1) – Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Catenin Beta 1 (Beta Catenin or CTNNB1) – Companies Involved in Therapeutics Development 21

Boston Biomedical Inc 21

Dicerna Pharmaceuticals Inc 21

Marina Biotech Inc 21

Propanac Biopharma Inc 22

Warp Drive Bio Inc 22

Catenin Beta 1 (Beta Catenin or CTNNB1) – Drug Profiles 23

Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis – Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

BBI-801 – Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

exisulind – Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

M-101 – Drug Profile 26

Product Description 26

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Leave a Reply